Lates News

Gilead Sciences announced its financial results for the second quarter of 2026 on August 4, 2026. Total revenue increased by 10% year-over-year to $7.8 billion, primarily driven by a 10% increase in product sales excluding Veklury, which reached $7.6 billion. Sales of HIV products grew by 12% to $5.7 billion, with Biktarvy sales rising by 7% to $3.8 billion.